



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61P 37/06 (2006.01)

(21) International Application Number:

PCT/EP2022/055080

(22) International Filing Date:

01 March 2022 (01.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21159860.2 01 March 2021 (01.03.2021) EP

(71) Applicant: **MORPHOSYS AG** [DE/DE]; Semmelweisstr.
7, 82152 Planegg (DE).

(72) Inventors: **STEIDL, Stefan**; Engelbertstr. 5a, 81241
München (DE). **HÄRTLE, Stefan**; Biberfeldstraße 3,
82291 Mammendorf (DE). **BOXHAMMER, Rainer**;
Birkenstraße 4a, 83059 Kolbermoor (DE).

(74) Agent: **SPILLER, Stephan**; MorphoSys AG, Semmel-
weisstr. 7, 82152 Planegg (DE).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION

Figure 1



(57) Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*